Accendra Health Misses Q2 Estimates, Guides to Lower Full-Year EBITDA, CEO to Retire
ACH sits 52% above its 52-week low of $1.84.
Summary
Accendra Health missed Q2 estimates with a $1.16 per-share loss, lowered full-year EBITDA guidance, and announced CEO Ed Pesicka's retirement by end of 2026.
Key Events · Earnings and Guidance · ACH
-
Q2 Earnings Miss
Q2 net revenue fell 10% YoY to $613.2M; GAAP loss from continuing operations was $89.1M ($1.16/share), missing expectations.
-
Full-Year Guidance Cut
2026 adjusted EBITDA guidance lowered to $300M-$320M (from prior implied ~$340M+); free cash flow now expected breakeven to slightly positive.
-
CEO Retirement Announced
CEO Ed Pesicka will retire by end of 2026; board has begun succession search, adding leadership uncertainty.
-
Adjusted EBITDA Decline
Q2 adjusted EBITDA dropped 38% YoY to $60.1M, driven by large commercial payor exit, volume/mix headwinds, and cost inflation.
Analysis · ACH · Trade & Services
Accendra Health reported a Q2 loss of $1.16 per share, missing expectations and underscoring ongoing financial strain. Revenue fell 10% year-over-year to $613 million, and adjusted EBITDA dropped 38% to $60 million. The company cut its full-year adjusted EBITDA guidance to $300-$320 million, down from prior expectations, and now expects free cash flow to be only breakeven to slightly positive. Adding to the uncertainty, CEO Ed Pesicka announced his retirement by year-end, leaving a leadership vacuum as the company navigates a challenging turnaround. The results and guidance cut signal deeper operational headwinds than previously anticipated, and the CEO departure removes a key architect of the recent debt restructuring.
At the time of this filing, ACH was trading at $2.80 on NYSE in the Trade & Services sector, with a market capitalization of approximately $214.4M. The 52-week trading range was $1.84 to $7.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.